JP2024505075A5 - - Google Patents

Info

Publication number
JP2024505075A5
JP2024505075A5 JP2023546011A JP2023546011A JP2024505075A5 JP 2024505075 A5 JP2024505075 A5 JP 2024505075A5 JP 2023546011 A JP2023546011 A JP 2023546011A JP 2023546011 A JP2023546011 A JP 2023546011A JP 2024505075 A5 JP2024505075 A5 JP 2024505075A5
Authority
JP
Japan
Prior art keywords
immune cells
manipulated
nlrc5
rfx5
mhc class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2023546011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505075A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014393 external-priority patent/WO2022165233A1/en
Publication of JP2024505075A publication Critical patent/JP2024505075A/ja
Publication of JP2024505075A5 publication Critical patent/JP2024505075A5/ja
Abandoned legal-status Critical Current

Links

JP2023546011A 2021-01-29 2022-01-28 同種細胞産物のT細胞認識を軽減するための、TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP及びRFXANKのうち1つ以上のノックダウン又はノックアウト Abandoned JP2024505075A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163143748P 2021-01-29 2021-01-29
US63/143,748 2021-01-29
US202163176818P 2021-04-19 2021-04-19
US63/176,818 2021-04-19
US202263267041P 2022-01-21 2022-01-21
US63/267,041 2022-01-21
PCT/US2022/014393 WO2022165233A1 (en) 2021-01-29 2022-01-28 KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS

Publications (2)

Publication Number Publication Date
JP2024505075A JP2024505075A (ja) 2024-02-02
JP2024505075A5 true JP2024505075A5 (cg-RX-API-DMAC7.html) 2025-02-03

Family

ID=80683153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546011A Abandoned JP2024505075A (ja) 2021-01-29 2022-01-28 同種細胞産物のT細胞認識を軽減するための、TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP及びRFXANKのうち1つ以上のノックダウン又はノックアウト

Country Status (9)

Country Link
US (1) US12577283B2 (cg-RX-API-DMAC7.html)
EP (1) EP4284918A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024505075A (cg-RX-API-DMAC7.html)
KR (1) KR20230142470A (cg-RX-API-DMAC7.html)
AU (1) AU2022212130A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204417A1 (cg-RX-API-DMAC7.html)
IL (1) IL303853A (cg-RX-API-DMAC7.html)
MX (1) MX2023008809A (cg-RX-API-DMAC7.html)
WO (1) WO2022165233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082306A1 (en) * 2021-02-03 2024-03-14 Bioheng Therapeutics Limited Novel chimeric antigen receptor and use thereof
US20260000761A1 (en) * 2022-01-19 2026-01-01 Nkarta, Inc. Engineered immune cells with enhanced potency and uses of same in immunotherapy
TW202340457A (zh) * 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
US20240042030A1 (en) * 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024023802A2 (en) * 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024153234A1 (en) * 2023-01-20 2024-07-25 Chengdu Ucello Biotechnology Co., Limited Engineered immune cells and uses thereof
AU2024315647A1 (en) * 2023-08-02 2026-02-12 Fate Therapeutics, Inc. Solid tumor targeting backbone promoting effector cell differentiation and function
WO2025049631A1 (en) * 2023-08-28 2025-03-06 Kyverna Therapeutics, Inc. Allogeneic car-t cell therapies and manufacture thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
CA2793753C (en) 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
JP6285553B2 (ja) 2013-08-26 2018-02-28 インノバイオファーム リミテッド 抗cd30キメラ抗原受容体およびその使用
WO2015130766A1 (en) 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
GB201413335D0 (en) 2014-07-28 2014-09-10 Azotic Technologies Ltd Agricultural methods
RU2017102769A (ru) 2014-07-29 2018-08-28 Пфайзер Инк. EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
WO2016142532A1 (en) 2015-03-11 2016-09-15 Cellectis Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
TWI700298B (zh) 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
CA2994746A1 (en) 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP2018531014A (ja) 2015-10-15 2018-10-25 アメリカ合衆国 抗cd30キメラ抗原受容体
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
BR112018014585A2 (pt) 2016-01-21 2018-12-11 Pfizer receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
CN109641037B (zh) 2016-04-13 2022-09-06 西安奥瑞单抗生物技术有限公司 抗psma抗体及其用途
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
JP7231158B2 (ja) 2016-10-19 2023-03-01 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント Cd133結合剤およびその使用
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
EP3583129B1 (en) 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
CN116836297A (zh) 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
JP7584127B2 (ja) 2018-04-26 2024-11-15 ベイラー カレッジ オブ メディスン 活性化された病原性t細胞およびnk細胞の選択的標的化のための自己/同種免疫防御受容体
KR102351623B1 (ko) 2018-05-14 2022-01-14 주식회사 엘지에너지솔루션 분리막 기재가 없는 분리막
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2020005837A1 (en) 2018-06-25 2020-01-02 The Trustees Of The University Of Pennsylvania Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
AU2019299555A1 (en) 2018-07-04 2021-02-25 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting FLT3, PD-1, and/or PD-L1
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
SG11202100838QA (en) 2018-07-26 2021-02-25 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using target specific fusion proteins
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
EA202191257A1 (ru) 2018-11-07 2021-12-06 Криспр Терапьютикс Аг Противораковая терапия на основе иммуноцитов, связывающих liv1
CN109468284A (zh) 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和psma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
JP2022510207A (ja) * 2018-12-02 2022-01-26 フェイト セラピューティクス,インコーポレイテッド 増強されたiPSC派生エフェクター細胞を使用した免疫療法
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
CN109680002A (zh) 2019-01-09 2019-04-26 上海怡豪生物科技有限公司 联合msln单链抗体和ccl19杀伤胃癌细胞的car载体及其构建方法和应用
CN109628492A (zh) 2019-01-09 2019-04-16 上海怡豪生物科技有限公司 联合MSLN单链抗体和PD-1mAb杀伤胃癌细胞的CAR载体及其构建方法和应用
KR20210116526A (ko) 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
PT3749338T (pt) 2019-01-16 2024-09-20 Caribou Biosciences Inc Anticorpo de bcma humanizado e células bcma-car-t
US11738050B2 (en) 2019-02-01 2023-08-29 Regents Of The University Of Minnesota Compounds binding to fibroblast activation protein alpha
MX2021010441A (es) 2019-03-01 2021-09-21 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
WO2020186204A1 (en) 2019-03-13 2020-09-17 Ulmert Hans David Staffan Prame binding molecules and uses thereof
CN113906133A (zh) * 2019-04-11 2022-01-07 菲特治疗公司 工程改造的iPSC和免疫效应细胞中的CD3重建
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
CA3147122A1 (en) 2019-07-12 2021-01-21 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Cldn18.2 antibody and use thereof
KR20220035190A (ko) 2019-07-17 2022-03-21 페이트 세러퓨틱스, 인코포레이티드 면역 효과기 세포 조작 및 이의 용도
CN111363046A (zh) 2020-03-11 2020-07-03 深圳宾德生物技术有限公司 靶向nkg2d的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用

Similar Documents

Publication Publication Date Title
US11712454B2 (en) Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogenous FOXP3 gene
Behrmann et al. Structure of the human APO‐1 gene
JP2022539248A (ja) 組換えad35ベクター及び関連遺伝子治療改善
JP2019531090A (ja) 改変されたvsv−gおよびそのワクチン
CN114746109A (zh) 靶向肿瘤新抗原性肽的免疫疗法
US20250319200A1 (en) Adenoviral gene therapy vectors
CA3186620A1 (en) Methods and compositions for editing the b2m locus in b cells
JP2024531234A5 (cg-RX-API-DMAC7.html)
EP4267200A1 (en) Adenoviral gene therapy vectors
Saito et al. Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene
Fabre Regulation of MHC expression
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
JP2025509974A (ja) 免疫不全fcgr1ノックアウトマウスモデル
Bhojnagarwala et al. synDNA vaccine against TCR chains and neoantigens for T cell lymphoma therapy
Chen et al. Humanized transgenic mice expressing HLA DR4‐DQ3 haplotype: reconstitution of phenotype and HLA‐restricted T‐cell responses
Schmitt et al. Cd4 T helper cells Instruct Lymphopenia-Induced Memory-Like CD8 T cells for control of acute LCMV infection
CN119220607B (zh) 编辑tim3基因获得功能强化的car-nk细胞的方法与应用
CN121801841A (zh) 一种tox基因敲除的新型til的制备方法和应用
JP2000505284A (ja) 形質導入されたヒト造血幹細胞
Lui et al. Prospects for ensuring acceptance of ES cell-derived tissues
’t Hart et al. Modeling MS in nonhuman primates
HK40013246A (en) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene